Nuvectis in-licenses late-stage oncology drugs and raises $115M in follow-on offering to fund pipeline expansion
Nuvectis acquired ex-China rights to oncology assets NXP100 and NXP200 and closed a $115M July 2026 follow-on offering with cash runway extending into 1H 2029.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day